Navigation Links
Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target

any diabetes drug for an eight- week period. Patients were then randomized to receive one of four once-daily doses of liraglutide (0.1, 0.3, 0.6, and 0.9 mg) or placebo. Baseline A1c levels ranged between 8.1 to 8.5%. The randomized, 14-week study showed statistically significant dose-dependent reductions in A1c levels (ranging from 0.79 to 1.85 percentage points - placebo adjusted, p<0.0001) after once- daily dosing of liraglutide monotherapy in these patients. Further, A1c levels below 7 percent were achieved by 22, 43, 62 and 75 percent of patients receiving liraglutide 0.1, 0.3, 0.6 and 0.9 mg/day compared with 9 percent of those receiving placebo. Additionally, in these normal-weight subjects (average BMI 23.9) no relevant changes in body weight or major or minor hypoglycemic events occurred in any study group.(1)

The main gastrointestinal adverse events in the high dose group versus placebo were: constipation (7% versus 9%), diarrhea (9% versus 4%), gastritis (7% vs. 0%) and nausea (7% versus 2%). No subject had a treatment-related increase in liraglutide antibodies.

About liraglutide

Currently in phase 3 clinical trials, liraglutide is a human analog of the naturally occurring hormone, Glucagon-Like Peptide-1 (GLP-1), which is rapidly broken down in the body and thus not practical as a therapy for type 2 diabetes. GLP-1 is released from the gastrointestinal tract upon ingestion of food. When glucose levels become too high, GLP-1 triggers the release of insulin from the pancreas and decreases the secretion of glucagon, a hormone that promotes glucose synthesis in the liver. GLP-1 releases insulin in a glucose-dependent manner, meaning that it only triggers insulin secretion if blood glucose is too high. This characteristic is thought to result in a low risk of hypoglycemia, which has been confirmed in a number of studies in which GLP-1 was infused intravenously or subcutaneously.

Novo Nordisk is a healthcare company and a world lead
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/22/2014)... BURLINGTON, Mass. , July 22, 2014  Decision Resources ... in Canada will remain relatively stagnant ... is despite the fact that percutaneous coronary intervention (PCI) volumes ... to other developed markets, such as the United ... growth will be largely driven by the increase in penetration ...
(Date:7/22/2014)... July 22, 2014 According ... "Process Spectroscopy Market (Technology Types - Near infrared (NIR) spectroscopy, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 ... in 2012 and is expected to grow at a CAGR ... North America was the largest contributor to global ...
(Date:7/22/2014)... 2014  Eyeon Therapeutics has received a Notice of ... a charged hydrophilic polymer developed at Particles Sciences, a ... to be safe and effective in a small trial ... "This first set of claims around the polymer and ... this technology into the commercial phase.  We have been ...
Breaking Medicine Technology:The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2
(Date:7/22/2014)... undergoing a minimally invasive hysterectomy using electric power morcellation, ... at the time of the procedure, according to a ... concern that this procedure, in which the uterus is ... of undetected malignancies. , Despite the commercial availability of ... the prevalence of malignancy at the time of electric ...
(Date:7/22/2014)... of Hematology (ASH) will present the Society,s highest honor, ... in Hematology, to Kanti R. Rai, MD, of the ... for his 50-year career combining landmark clinical leukemia research, ... care. , The Wallace H. Coulter Award for ... who has been a vital contributor to the field ...
(Date:7/22/2014)... mechanisms with cancer, according to a new report by ... , published in PLOS ONE on July ... very same inhibitors of apoptosis, or cell destruction, in ... diseases. Henry Kaminski, M.D. , chair of the ... and Health Sciences (SMHS), as well as colleagues from ...
(Date:7/22/2014)... Ticket Down is a reliable source ... Fedex Field in Landover, MD. There has never been a ... international soccer. After the success of the American national soccer team ... and well. One way that fans of the world’s sport will ... the 2014 Guinness International Champions Cup. The tournament will kick off ...
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) products has ... novel medical indications created and due to more cosmetic ... physical appearance is extremely valued. Although the BoNT market ... companies and technologies are setting ground for biosuperiors and ... price of 1st-gen products under pressure, only innovation is ...
Breaking Medicine News(10 mins):Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4
... April 24 Actavis Group, the,international generic pharmaceuticals ... a case study on the Company and its ... Actavis, ,Winning,formula," was presented in an MBA class ... will be made available to business,schools around the ...
... Was Served, -, LOS ANGELES, April 23 ... against Yolanda McGriff, a Los Angeles-,based healthcare worker who ... a low-income, disabled veteran. McGriff was arrested for,trespass-related violations ... employer, a man who lived in what used to ...
... Reflecting the growing concern,over health care costs and ... afford a comfortable retirement decreased over the past ... of the Retirement Confidence Survey(R),(RCS), according to just-released ... News Release, go to:, http://www.prnewswire.com/mnr/ebri/32335/ , The ...
... of image-guided ... therapy, PALO ALTO, Calif., April 23 Varian Medical,Systems ... than 60 orders for,its new RapidArc radiotherapy product for faster ... but have also come in from Europe and Asia,since the ...
... the voice of the,public, Hero Nutritionals, Inc. is launching ... adults. Hero Nutritionals, manufacturer of Yummi,Bears, the original gummy ... moms buying Yummi Bears, for an adult version of ... Yummi Bears is the,nation,s #1 & best tasting gummy ...
... using a bionic boot found that during walking, the ankle ... of energy compared to isolated muscles---in other words, the spring ... efficiently. , While much has been done measuring the efficiency ... measure the energy efficiency of a body part such as ...
Cached Medicine News:Health News:Harvard Business School Publishes a Case Study on Robert Wessman and Actavis 2Health News:Harvard Business School Publishes a Case Study on Robert Wessman and Actavis 3Health News:Case Dropped Against Healthcare Worker Who Was Arrested While Providing Care to an Elderly, Disabled Man in Los Angeles Home 2Health News:Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers' Record Drop in Retirement Confidence 2Health News:Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers' Record Drop in Retirement Confidence 3Health News:Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers' Record Drop in Retirement Confidence 4Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 2Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 3Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 4Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 5Health News:Hero Nutritionals Introduces a New Adult Vitamin for the Taste Buds 2Health News:The spring in your step is more than just a good mood 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: